These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16581327)

  • 1. Statin safety: an appraisal from the adverse event reporting system.
    Davidson MH; Clark JA; Glass LM; Kanumalla A
    Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin safety: lessons from new drug applications for marketed statins.
    Jacobson TA
    Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
    Jones PH; Davidson MH
    Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
    Clark JA; Humphries JE; Crean S; Reynolds MW
    Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
    McKenney JM; Davidson MH; Jacobson TA; Guyton JR;
    Am J Cardiol; 2006 Apr; 97(8A):89C-94C. PubMed ID: 16581336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
    Fraunfelder FW; Richards AB
    Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
    Alsheikh-Ali AA; Ambrose MS; Kuvin JT; Karas RH
    Circulation; 2005 Jun; 111(23):3051-7. PubMed ID: 15911706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin safety and drug interactions: clinical implications.
    Bottorff MB
    Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Jamal SM; Eisenberg MJ; Christopoulos S
    Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins, cardiovascular disease, and drug safety.
    Gotto AM
    Am J Cardiol; 2006 Apr; 97(8A):3C-5C. PubMed ID: 16581326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
    García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.
    Goettsch WG; Heintjes EM; Kastelein JJ; Rabelink TJ; Johansson S; Herings RM
    Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):435-43. PubMed ID: 16761304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.
    McAfee AT; Ming EE; Seeger JD; Quinn SG; Ng EW; Danielson JD; Cutone JA; Fox JC; Walker AM
    Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):444-53. PubMed ID: 16761308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.